Showing results 1 to 2 of 2
| Title | Author(s) | Issue Date | |
|---|---|---|---|
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia Journal:Clinical Lymphoma, Myeloma and Leukemia | 1-Sep-2023 | ||
Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial Journal:Journal of Clinical Oncology | 1-Jun-2025 |